Aredia

(pamidronate disodium)

PreclinicalSmall molecule

HHikma Pharmaceuticals LLC

Aredia is one of 3 small molecule programs targeting Avascular Necrosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Avascular NecrosisActive, not recruiting

Avascular NecrosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Avascular Necrosis

#DrugCompanyPhaseTrials

Trental

VValidus Pharmaceuticals

Approved

—2

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—3

Aredia

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple Myeloma3 trials

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00033332

Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma

Completed·—·Phase 2·NCT00004088·77 enrolled

Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00124605·24 enrolled

Avascular Necrosis1 trial

The Use of Bisphosphonates in the Treatment of Avascular Necrosis of the Femoral Head

Terminated·TThe Hospital for Sick Children·N/A·NCT02007915·20 enrolled

Synovitis1 trial

Efficacy of Bisphosphonates in Patients With Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome

Completed·PPeking Union Medical College Hospital·Phase 1·NCT02544659·30 enrolled

Breast Cancer1 trial

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Completed·HHackensack Meridian Health·Phase 2·NCT00004906

Regulatory

FDA Approval Timeline[4]

Oct 31, 1991

AREDIA

NDA NDA020036

Mar 4, 2002

PAMIDRONATE DISODIUM

NDA NDA021113

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for pamidronate disodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pamidronate disodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pamidronate disodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021113). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Hikma Pharmaceuticals LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHikma Pharmaceuticals LLC

Aredia

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple Myeloma3 trials

Avascular Necrosis1 trial

Synovitis1 trial

Breast Cancer1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News